RxDoctor Payments Data

Ashley Sandoval, MD

Allergy & Immunology · Long Beach, CANPI 1720408958

Payments from drug & device makers

$3,752in general payments, 2019–2025

Across 112 payments — averaging $33.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$863
  • GSK$480
  • AstraZeneca$434
  • Amgen$388
  • Alk-abello, Inc$301
  • Regeneron Healthcare Solutions, Inc.$285
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,67398%
  • Education$792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,752 in reported general payments places this provider in the 55th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$28,784
Medicare patients
95
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab31$127,616
Dupixent SyringeDupilumab11$40,802
NucalaMepolizumab11$38,690
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$38,390
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$31,041
Spiriva RespimatTiotropium Bromide24$16,985
DuleraMometasone/Formoterol16$8,535
Breo ElliptaFluticasone/Vilanterol15$6,002
BreynaBudesonide/Formoterol Fumarate14$5,037
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,697
Azelastine Hcl80$3,156
Azelastine-FluticasoneAzelastine/Fluticasone15$2,298
Wixela InhubFluticasone Propion/Salmeterol19$1,820
Ipratropium Bromide44$1,662
Fluticasone Propionate41$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta$480$75,73363 claims
CSL BehringPrivigen$187$38,39015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →